مباشر
FierceBiotechMcKesson swaps minority stake in surgical unit to Apollo Funds for $1.25BFierceBiotechAcuityMD raises $80M to help bolster AI in the medtech industryFierceBiotechAACR: NCI leader Letai battles ‘misinformation’ to assure anxious researchers that ‘funding is strong’FierceBiotechMerck goes with Google for AI push, striking enterprise partnership worth up to $1BThermo FisherGlobal Cloud ELN Service Market | USA, China, India Lead | Thermo Fisher Scientific, Agilent Technologies, Dassault Systèmes Drive Digital Lab Transformation - PR NewswireAgilentAgilent’s Expanding Role in Advanced Therapeutics - Contract PharmaBioWorldAI opens the way to systematic risk assessment of zoonotic potential of virusesBioWorldSingularity Pharma discloses new mitragynine analoguesBioWorldJiangsu Vcare Pharmatech identifies new IL-17A inhibitorsBioWorldRuijin Hospital and Shanghai Jiao Tong University discover GSPT1 degradation inducersAgilentAgilent Technologies (A) Launches Key Cancer Diagnostic Tool - GuruFocusFierceBiotechNovartis narrows focus for anticoagulant after failure to best Eliquis in phase 3 trial
eLife ٢٨ نوفمبر ٢٠٢٥

Human <i>RAP2A</i> homolog of the <i>Drosophila</i> asymmetric cell division regulator <i>Rap2l</i> targets the stemness of glioblastoma stem cells

Human RAP2A homolog of the Drosophila asymmetric cell division regulator Rap2l targets the stemness of glioblastoma stem cells

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.